Current portfolio

Karo Pharma

A leading specialty pharmaceutical company in the Nordics

Karo Pharma develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.

  • Sektor
    Healthcare
  • Land
    Sweden
  • Ansvarig Advisor
    Erika Henriksson
  • Fond
    EQT VIII
  • Entry
    2019
  • Web
3

Private Capital

Karo Pharma

  • Societal Contribution

  • 3Good health and well-being
  • 8Decent work and economic growth
  • 12Responsible consumption and production
Logo

About Karo Pharma
Karo Pharma sells and markets a portfolio of everyday healthcare products that help prevent illnesses and treat health problems. The portfolio consists of original brands with strong market positions and comprises both prescription drugs (Rx) as well as consumer products (OTC) within six distinct categories - Pain, Cough & Cold, Dermatology, Intimate Care, Footcare, Speciality products, and Wellness. Karo Pharma's products have a strong position in the Nordic regions and the company has successfully expanded its direct distributions network to several other countries in Western Europe both through organic growth and acquisitions. Overall, Karo Pharma's products are sold to sixty different markets worldwide. Karo Pharma was founded in 1987 and is headquartered in Stockholm, Sweden. The company has been listed on Nasdaq Stockholm since 1998.

Market trends and drivers
The large specialty pharmaceutical market demonstrates stable growth over the cycles and high resilience during economic downturns. The market offers attractive growth opportunities, both organically driven by underlying patient-critical demand, and inorganically through a generally high M&A activity as a result of the continued consolidation in the pharmaceutical industry.

Investment potential
Accelerate organic growth in existing portfolio through commerical and digital focus, primarily on larger "Hero" brands with international presence and potential. Continue consolidating the fragmented speciality pharma and consumer health market by acquiring pan-European brands in core categories with growth potential, targeting attractive organic growth outlook at exit. Increase share of OTC in the overall portfolio. Drive operational improvements including increasing gross margin through CMO and logistics consolidation, as well as driving operating leverage while strengthening Karo Pharma's organization and capabilities.

Board of directors

  • Chairperson
    Pat Smallcombe
  • Board member
    Flemming Ornskov
  • Board member
    Erika Henriksson
  • Board member
    Kristofer Tonström
  • Board member
    Uta Kemmerich-Keil
  • Board member
    Mark Keatley

Management

  • CEO
    Christoffer Lorenzen
  • CFO
    Jon Johnsson

Prenumerera

Prenumerera på EQT:s press releaser, regulatoriska press releaser och updates.

Typ av nyheter
Preferred language
EQT logo
En syftesdriven global investeringsorganisation
© EQT AB 2021. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180